<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>BACKGROUND: The UK Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study showed that <z:chebi fb="0" ids="6801">metformin</z:chebi> decreases mortality compared to diet alone in overweight patients with type 2 <z:hpo ids='HP_0000819'>diabetes mellitus</z:hpo> </plain></SENT>
<SENT sid="1" pm="."><plain>Since then, it has been the first-line treatment in overweight patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="2" pm="."><plain>However, <z:chebi fb="0" ids="6801">metformin</z:chebi>-sulphonylurea bitherapy may increase mortality </plain></SENT>
<SENT sid="3" pm="."><plain>METHODS AND FINDINGS: This meta-analysis of randomised controlled trials evaluated <z:chebi fb="0" ids="6801">metformin</z:chebi> efficacy (in studies of <z:chebi fb="0" ids="6801">metformin</z:chebi> versus diet alone, versus placebo, and versus no treatment; <z:chebi fb="0" ids="6801">metformin</z:chebi> as an add-on therapy; and <z:chebi fb="0" ids="6801">metformin</z:chebi> withdrawal) against <z:e sem="disease" ids="C1301700" disease_type="Disease or Syndrome" abbrv="">cardiovascular morbidity</z:e> or mortality in patients with type 2 <z:mp ids='MP_0002055'>diabetes</z:mp> </plain></SENT>
<SENT sid="4" pm="."><plain>We searched Medline, Embase, and the Cochrane database </plain></SENT>
<SENT sid="5" pm="."><plain>Primary end points were <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality and cardiovascular <z:hpo ids='HP_0011420'>death</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>Secondary end points included <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarctions</z:hpo>, <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001297'>strokes</z:hpo>, <z:hpo ids='HP_0001635'>congestive heart failure</z:hpo>, <z:hpo ids='HP_0004950'>peripheral vascular disease</z:hpo>, leg <z:mpath ids='MPATH_686'>amputations</z:mpath>, and microvascular complications </plain></SENT>
<SENT sid="7" pm="."><plain>Thirteen randomised controlled trials (13,110 patients) were retrieved; 9,560 patients were given <z:chebi fb="0" ids="6801">metformin</z:chebi>, and 3,550 patients were given conventional treatment or placebo </plain></SENT>
<SENT sid="8" pm="."><plain><z:chebi fb="0" ids="6801">Metformin</z:chebi> did not significantly affect the primary outcomes <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality, risk ratio (RR)=0.99 (95% CI: 0.75 to 1.31), and cardiovascular mortality, RR=1.05 (95% CI: 0.67 to 1.64) </plain></SENT>
<SENT sid="9" pm="."><plain>The secondary outcomes were also unaffected by <z:chebi fb="0" ids="6801">metformin</z:chebi> treatment: <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001658'>myocardial infarctions</z:hpo>, RR=0.90 (95% CI: 0.74 to 1.09); <z:hpo ids='HP_0000001'>all</z:hpo> <z:hpo ids='HP_0001297'>strokes</z:hpo>, RR=0.76 (95% CI: 0.51 to 1.14); <z:hpo ids='HP_0001635'>heart failure</z:hpo>, RR=1.03 (95% CI: 0.67 to 1.59); <z:hpo ids='HP_0004950'>peripheral vascular disease</z:hpo>, RR=0.90 (95% CI: 0.46 to 1.78); leg <z:mpath ids='MPATH_686'>amputations</z:mpath>, RR=1.04 (95% CI: 0.44 to 2.44); and microvascular complications, RR=0.83 (95% CI: 0.59 to 1.17) </plain></SENT>
<SENT sid="10" pm="."><plain>For <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality and cardiovascular mortality, there was significant <z:hpo ids='HP_0001425'>heterogeneity</z:hpo> when including the UK Prospective <z:mp ids='MP_0002055'>Diabetes</z:mp> Study subgroups (I(2)=41% and 59%) </plain></SENT>
<SENT sid="11" pm="."><plain>There was significant interaction with sulphonylurea as a concomitant treatment for <z:hpo ids='HP_0001658'>myocardial infarction</z:hpo> (p=0.10 and 0.02, respectively) </plain></SENT>
<SENT sid="12" pm="."><plain>CONCLUSIONS: Although <z:chebi fb="0" ids="6801">metformin</z:chebi> is considered the gold standard, its benefit/risk ratio remains uncertain </plain></SENT>
<SENT sid="13" pm="."><plain>We cannot exclude a 25% reduction or a 31% increase in <z:hpo ids='HP_0000001'>all</z:hpo>-cause mortality </plain></SENT>
<SENT sid="14" pm="."><plain>We cannot exclude a 33% reduction or a 64% increase in cardiovascular mortality </plain></SENT>
<SENT sid="15" pm="."><plain>Further studies are needed to clarify this situation </plain></SENT>
</text></document>